Literature DB >> 31935717

SERINC5 Is an Unconventional HIV Restriction Factor That Is Upregulated during Myeloid Cell Differentiation.

Ariane Zutz1, Christian Schölz2, Stephanie Schneider1, Virginia Pierini3, Maximilian Münchhoff1,4, Kathrin Sutter5, Georg Wittmann6, Ulf Dittmer5, Rika Draenert7,4, Johannes R Bogner7,4, Oliver T Fackler3,8, Oliver T Keppler1,4.   

Abstract

Classical antiviral restriction factors promote cellular immunity by their ability to interfere with virus replication and induction of their expression by proinflammatory cytokines such as interferons. The serine incorporator proteins SERINC3 and SERINC5 potently reduce the infectivity of HIV-1 particles when overexpressed, and RNA interference or knockout approaches in T cells have indicated antiviral activity also of the endogenous proteins. Due to lack of reagents for detection of endogenous SERINC proteins, it is still unclear whether SERINC3/5 are expressed to functionally relevant levels in different primary target cells of HIV infection and how the expression levels of these innate immunity factors are regulated. In the current study, analysis of SERINC3/5 mRNA steady-state levels in primary lymphoid and monocyte-derived cells revealed selective induction of their expression upon differentiation of myeloid cells. Contrary to classical antiviral restriction factors, various antiviral α-interferon subtypes and proinflammatory interleukins had no effect on SERINC levels, which were also not dysregulated in CD4+ T cells and monocytes isolated from patients with chronic HIV-1 infection. Notably, HIV-1 particles produced by terminally differentiated monocyte-derived macrophages with high SERINC5 expression, but not by low-expressing monocytes, showed a Nef-dependent infectivity defect. Overall, these findings suggest endogenous expression of SERINC5 to antivirally active levels in macrophages. Our results classify SERINC5 as an unconventional HIV-1 restriction factor whose expression is specifically induced upon differentiation of cells towards the myeloid lineage.
© 2020 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Adaptive immunity; HIV; Innate restriction factor; Myeloid cell differentiation; SERINC5

Mesh:

Substances:

Year:  2020        PMID: 31935717      PMCID: PMC7900780          DOI: 10.1159/000504888

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  30 in total

1.  The Evolutionary Histories of Antiretroviral Proteins SERINC3 and SERINC5 Do Not Support an Evolutionary Arms Race in Primates.

Authors:  Ben Murrell; Thomas Vollbrecht; John Guatelli; Joel O Wertheim
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

2.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

3.  Systematic identification of type I and type II interferon-induced antiviral factors.

Authors:  Su-Yang Liu; David Jesse Sanchez; Roghiyh Aliyari; Sun Lu; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

4.  The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.

Authors:  Birthe Trautz; Virginia Pierini; Rebecka Wombacher; Bettina Stolp; Amanda J Chase; Massimo Pizzato; Oliver T Fackler
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

6.  Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef.

Authors:  Oliver T Keppler; Ina Allespach; Lismarie Schüller; David Fenard; Warner C Greene; Oliver T Fackler
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication.

Authors:  A Foli; M W Saville; M W Baseler; R Yarchoan
Journal:  Blood       Date:  1995-04-15       Impact factor: 22.113

8.  Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.

Authors:  Kerry J Lavender; Kathrin Gibbert; Karin E Peterson; Erik Van Dis; Sandra Francois; Tyson Woods; Ronald J Messer; Ali Gawanbacht; Janis A Müller; Jan Münch; Katie Phillips; Brent Race; Michael S Harper; Kejun Guo; Eric J Lee; Mirko Trilling; Hartmut Hengel; Jacob Piehler; Jens Verheyen; Cara C Wilson; Mario L Santiago; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

9.  The Urinary Bladder Transcriptome and Proteome Defined by Transcriptomics and Antibody-Based Profiling.

Authors:  Masato Habuka; Linn Fagerberg; Björn M Hallström; Fredrik Pontén; Tadashi Yamamoto; Mathias Uhlen
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

10.  Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.

Authors:  Yuanfei Wu; Balaji Olety; Eric R Weiss; Elena Popova; Hikaru Yamanaka; Heinrich Göttlinger
Journal:  mBio       Date:  2019-06-11       Impact factor: 7.867

View more
  6 in total

1.  Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection.

Authors:  Saina Beitari; Qinghua Pan; Andrés Finzi; Chen Liang
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 2.  HIV-1 restriction by SERINC5.

Authors:  Lucía Cano-Ortiz; Tom Luedde; Carsten Münk
Journal:  Med Microbiol Immunol       Date:  2022-03-25       Impact factor: 3.402

3.  The Nef Protein of the Macrophage Tropic HIV-1 Strain AD8 Counteracts Human BST-2/Tetherin.

Authors:  Sebastian Giese; Scott P Lawrence; Michela Mazzon; Bernadien M Nijmeijer; Mark Marsh
Journal:  Viruses       Date:  2020-04-18       Impact factor: 5.048

Review 4.  The Emerging Role of the Serine Incorporator Protein Family in Regulating Viral Infection.

Authors:  Shaofen Xu; Zhichao Zheng; Janak L Pathak; Haoyu Cheng; Ziliang Zhou; Yanping Chen; Qiuyu Wu; Lijing Wang; Mingtao Zeng; Lihong Wu
Journal:  Front Cell Dev Biol       Date:  2022-04-01

5.  Coelacanth SERINC2 Inhibits HIV-1 Infectivity and Is Counteracted by Envelope Glycoprotein from Foamy Virus.

Authors:  Pavitra Ramdas; Vipin Bhardwaj; Aman Singh; Nagarjun Vijay; Ajit Chande
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

Review 6.  Host Restriction Factors Modulating HIV Latency and Replication in Macrophages.

Authors:  Isabel Pagani; Pietro Demela; Silvia Ghezzi; Elisa Vicenzi; Massimo Pizzato; Guido Poli
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.